The EMA's Committee for Medicinal Products for Human Use (CHMP) gives its blessing to Celgene's (NASDAQ:CELG) oral multiple myeloma treatment pomalidomide based on data from a Phase 3 trial. The committee also adopts a positive opinion for Aegerion's (AEGR) HoFH treatment LOJUXTA and says new data does not support the contention that Sanofi's (NASDAQ:SNY) Lantus increases the risk of cancer. AEGR + 0.92% premarket.